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Abstract: Herein, we describe the synthesis, biological evaluation and molecular docking of the selective PPARβ/δ 
antagonist (4-methyl-2-(4-(trifluoromethyl)phenyl)-N-(2-(5-(trifluoromethyl)-pyridin-2-ylsulfonyl)ethyl)thiazole-5-
carboxamide)), CC618. Results from in vitro luciferase reporter gene assays against the three known human PPAR subtypes 
revealed that CC618 selectively antagonizes agonist-induced PPARβ/δ activity with an IC50 = 10.0 μM. As observed by LC-
MS/MS analysis of tryptic digests, the treatment of PPARβ/δ with CC618 leads to a covalent modification of Cys249, 
located centrally in the PPARβ/δ ligand binding pocket, corresponding to the conversion of its thiol moiety to a 5-
trifluoromethyl-2-pyridylthioether. Finally, molecular docking is employed to shed light on the mode of action of the 
antagonist and its structural consequences for the PPARβ/δ ligand binding pocket. 
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Abbreviations: PPAR; peroxisome proliferator-activated receptor, LC-MS; liquid chromatography – mass spectrometry, LBP; ligand-
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Introduction 
The peroxisome proliferator-activated receptors (PPARα, 
PPARβ/δ and PPARγ, NR1C1-3) belong to the nuclear 
hormone receptor superfamily and function as ligand-
activated transcription factors [1]. The PPAR receptor 
subtypes display tissue-specific distribution patterns, with 
PPARβ/δ being the most abundant in skeletal muscle. The 
receptors play key roles in the induction of genes involved 
in carbohydrate and lipid metabolism and storage [2]. 
PPARs also impart on the processes of wound healing, cell 
differentiation and cancer [3-5]. Fatty acids and some of 
their metabolites, as well as synthetic ligands, can modulate 
transcriptional activity through the PPARs, rendering 
support for the notion that these receptors function as 
sensors for both endogenously and exogenously derived 
ligands [6]. The synthesis and development of selective 
ligands have proved instrumental in understanding the 
biological roles of the PPARs [7]. In the early days of PPAR 
research, the use of selective agonists against the three 
known PPAR subtypes was particularly important [8]. In the 
context of PPARβ/δ, the carboxylic acid GW501516 (1, 
Figure 1) [9,10] has seen widespread use as a 
pharmacological tool. Later, potent and selective PPARα 
and PPARγ antagonists, such as GW6471 (2) [11] and 
GW9662 (3) [12], were introduced (Figure 1). Recent 
evidence for the involvement of PPARβ/δ in additional  
cellular functions [13-16] justifies the need for further 
development of antagonistic modulators of the β/δ–subtype 
[17].  
In 2008, Shearer et al. identified GSK0660 (4) via a high-
throughput screen against PPARs of a GlaxoSmithKline in-
house compound collection. GSK0660 (4) displayed an IC50 
value of 155 nM against PPARβ/δ, and nearly ten-fold 
selectivity over the other PPAR subtypes. The antagonistic 
properties of GSK0660 (4) were established through the 
observation of downregulation of GW501516-induced 
transcription of bona fide PPARβ/δ target genes. However, 
due to rapid clearance in rodents, GSK06660 (4) was not 
suited for further in vivo studies [18]. Later, Müller and 
coworkers used GSK0660 (4) as a lead-compound for 
structure-activity studies leading to e.g. the analogue ST247 
(5), with improved bioavailability and binding affinity 
[19,20]. The same research group recently developed the 
acrylonitrile compound DG172 (6) which exhibited potent 
PPARβ/δ antagonism and oral bioavailability [21]. As 
carboxylic acids are canonical agonists of the PPAR 
receptors, it is notable that also SR13904 (7) [22], reported 
by Zaveri et al. as well as the acid 3a (8) [23], reported by 
Kasuga et al., exhibited PPARβ/δ antagonism. In 2010, 
Shearer et al. reported the potent PPARβ/δ antagonist 
GSK3787 (9) [24] which displayed good oral 
pharmacokinetic properties. This compound was shown to 
contain a reactive moiety, resulting in the covalent 
modification of Cys249, a cysteine located centrally in the 

















Figure 1. PPARβ/δ modulators. The selective PPARβ/δ agonist GW501516 (1), known PPAR antagonists (2 – 9) and CC618 (10a).
Results and Discussion 
Synthesis of the ligands 
In connection with our interest in developing potent PPAR 
agonists [25-27] and antagonists [28], we noted that the 
presence of a thiazole- or an oxazole heterocycle connected 
to an electron-poor phenyl ring appeared to be beneficial for 
the binding of agonists, such as GW501516 (1) to the 
hydrophobic moieties in the LBP of PPARβ/δ [10,29]. We 
envisioned that combining the arylthiazole moiety found in 
the potent and selective PPARβ/δ agonist GW501516 (1) 
with the 5-trifluoromethyl-2-pyridylsulfone moiety of 
GSK3787 (9) would result in antagonism against PPARβ/δ 
[28].  
 
We thus synthesized CC618 (10a), starting with the 
condensation of thioamide 11 and α-chloro-β-ketoester 12, 
as previously described [10], followed by basic hydrolysis, 
to give acid 14. Reacting 14 with the ammonium 
trifluoroacetate salt 15a [24] under peptide coupling 
conditions [30], afforded target compound 10a (Scheme 1). 
In a similar approach, we prepared an analogue of CC618, 
10b, lacking the 5-trifluoromethyl group on the pyridine 
ring. 
 
In vitro evaluations of the ligands 
The antagonistic properties of CC618 (10a) against the three 
known PPARs were first investigated in luciferase reporter 




























































































Scheme 1. Synthesis of the ligands. The synthesis of CC618 (10a) 
and analog 10b: (a) EtOH, Δ; (b) NaOH (aq), THF, Δ; (c) 15a or 
15b, Et3N, DCC, HOBt, CH2Cl2. 
In the PPARβ/δ-expressing cells, CC618 antagonized the 
effects of 4 nM of GW501516 with an IC50 = 10.0 μM. In 
this assay, the previously reported antagonist GSK3787 (9) 
displayed an IC50 = 5.0 μM (Figure 2A). The analog 10b, 
lacking the 5-trifluoromethyl group, did not display any 
antagonistic effects (see Supporting Information, Figure S1). 
On the other hand, neither CC618 (10a) nor GSK3787 (9) 
displayed any agonistic effects in our assay (Figure 2B). 
Furthermore, in Cos-1 cells expressing PPARα, only weak 
antagonistic effects were observed upon co-treatments of 
10a at various concentrations and 200 μM of bezafibrate 
[31]. An even weaker antagonism was observed in Cos-1 
cells expressing PPARγ, in the presence of various 
concentrations of 10a and 10 μM of rosiglitazone [32]. (see 
Figures S3 and S4 in the Supporting Information). These 
results demonstrate that CC618 (10a) is a selective PPARβ/δ 
antagonist. 
 
CC618 covalently modifies Cys249 in PPARβ/δ  
To further investigate the fate of the PPARβ/δ receptor upon 
treatment with CC618 (10a) or GSK3787 (9), we performed 
LC-MS/MS analyses of the peptides obtained by reductive 
alkylation and trypsination of PPARβ/δ, after a 15 min 
treatment with 10 μM of CC618 (10a) or GSK3787 (9) (see 
Experimental section for details). In both cases we found 
that the mass of Cys249 increased by 145 Da, as evidenced 
by the y-ion series (Figure 3). This mass difference 
corresponds to the addition of a trifluoromethylpyridyl 
fragment to the cysteine, with concurrent loss of the thiol 
proton. These results are in accordance with previous mass 




Figure 2. In vitro evaluation of the ligands. Effects of CC618 (10a) and GSK3787 (9) on PPARβ/δ in Cos-1 cells. A: Antagonist 
measurements (versus transcription induced with 4 nM GW501516). B: Agonist measurements (10a or 9 alone). The maximum response 
of the assay was determined as shown in Figure S2 in the Supporting Information. 


















CC618 (10a): R = CF3
15a, R = CF3
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RT: 32.11 min, ITMS, CID@35.00, Charge = +2, Monoisotopic m/z = 671.77008 Da (-2.46 mmu/-3.67 ppm), MH
+ = 1342.53288 Da, Match Tolerance = 0.6 Da.
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Figure 3. LC-MS/MS analysis of PPARβ/δ treated with CC618 (10a). Representative MS/MS spectrum of the peptide 
CmQcTTVETVR (residues 249 – 258, Cm = modified Cys249, c = carboxymethylated Cys251), obtained from tryptic digestion of human 
PPARβ/δ after incubation with 10 µM of 10a. Comparison of the mass of the tryptic peptide MH+ and ion y9+, indicates that Cys249 has 
an increased mass of 145.13369 Da corresponding, within the match tolerance, to that of the 5-trifluoromethyl-2-pyridyl fragment. 
The presence of a reactive cysteine located centrally in the 
PPARβ/δ ligand binding pocket is a known trait, conserved 
throughout the PPARs [33]. The reactivity of the 5-
trifluoromethyl-2-pyridylsulfone moiety towards a thiol or a 
thiolate, on the other hand, may be rationalized through a 
nucleophilic aromatic substitution on an electron-poor 2-
pyridylsulfone, also called an ipso-substitution. In 
substitution reactions of alkylsulfonyl aromatics with 
thiolates or alkoxides, the sulfone moiety acts as the leaving 







Scheme 2. Mechanistic insight. Schematic representation of a 
nucleophilic aromatic substitution at the 2-position of a 5-R-2-
(methylsulfonyl)pyridine, in which R = H, CF3. 
The reactivity of the compounds 9 and 10a towards 
nucleophiles, compared to simple arylsulfones, should thus 
be enhanced by the electron-withdrawing natures of both the 
pyridine nitrogen and the 5-trifluoromethyl group [35]. In a 
chemical context, a 5-H pyridylsulfone is reactive towards 
alkali metal alkoxide nucleophiles [34], but as compound 
10b did not display any antagonistic effects in the reporter 
assay, the presence of the 5-trifluoromethyl group on the 
pyridine ring appears to be necessary for the observed 
reactivity with Cys249. However, the observed effect of the 
presence of the 5-trifluoromethyl group, in the context of the 




In order to visualize and compare the receptor-ligand 
interactions of CC618 (10a) and GSK3787 (9) prior to an 
eventual reaction with Cys249, we docked the intact ligands 
to the PPARβ/δ LBD (PDB: 3GZ9) using Molsoft ICM [36]. 
As depicted in Figures 4 and 5, CC618 (10a) and GSK3787 
(9) are found to bind with similar orientations in relation to 
the LBP, with C–S distances of 4.3 Å and 3.7 Å, 
respectively, between their C-2 pyridine ring carbons and 
the sulfur atom of Cys249. The 5-trifluoromethyl-2-
pyridylsulfone moieties of both compounds occupy the arm 
of the LBP leading to the residues Tyr473, His413 and 
His287. Canonically, these residues accommodate the fatty 
acid carboxylate head group and form a hydrogen bonding 
network that is thought to be responsible for the stabilization 
of helix 12, through Tyr473 - a central trait in the pathway 




















perturbation of this stabilization been hypothesized to be a 
mechanism of nuclear receptor antagonism [38]. 
  
Figure 4. Docking of CC618 (10a). CC618 (10a) docked into 
PPARβ/δ (PDB: 3GZ9). Color coding of atoms: Red O, blue N, 
grey H, green F, mustard S and beige C in CC618 (10a); white C in 
PPARβ/δ. The coloring of the ribbons representing the PPARβ/δ 
backbone is purple, blue, green, yellow, orange and red from N-
terminal to C-terminal. 
  
Figure 5. Docking of GSK3787 (9). GSK3787 (9) docked into 
PPARβ/δ (PDB: 3GZ9). Color coding of atoms: Red O, blue N, 
grey H, green F, mustard S and beige C in GSK3787 (9); 
white/pink C in PPARβ/δ. The coloring of the ribbons representing 
the PPARβ/δ backbone is purple, blue, green, yellow, orange and 
red from N-terminal to C-terminal. 
Currently, there are no single crystal x-ray structures of 
PPARβ/δ in complex with an antagonist available in the 
RCSB Protein Data Bank. Thus, we chose to employ the 
covalent docking protocol CovDock [39] implemented in 
the Schrödinger Suite [40] (see Supporting Information for 
details) in order to visualize possible conformational states 
of the Cys249 thioether resulting from a reaction with 
compounds 9 or 10a, assuming that their chemical reactivity 
(vide supra) is relevant in the context of the protein. The 
three lowest energy poses of the 5-trifluoromethyl-2-pyridyl 
thioether (based on their Prime Energy property) are shown 
in Figure 6. The obtained possible conformations of the 5-
trifluoromethyl-2-pyridyl thioether in the PPARβ/δ LBP 
indicate that the covalently attached fragment may perturb 
Tyr473, His413 or His287 (and thus destabilize helix 12). It 
is also possible that the 5-trifluoromethyl-2-pyridyl thioether 
causes receptor inhibition by impeding the access of 




Figure 6. Covalent docking. Three favorable poses (based on their 
Prime-energy property) of the 5-trifluoromethyl-2-pyridyl thioether 
resulting from the covalent modification of Cys249 of PPARβ/δ 
(PDB: 3GZ9), generated with CovDock [39] from the Schrödinger 
Suite [40]. Color coding of atoms: Red O, blue N, white H, cyan F, 
yellow S and grey C. The coloring of the ribbons representing the 
PPARβ/δ backbone is brown, orange, yellow, green, blue and 
purple from N-terminal to C-terminal.  
Conclusions 
We have described the synthesis and biological evaluation 
of the selective PPARβ/δ antagonist CC618 (10a). The 
inhibitory effect of 10a did not exceed that of GSK3787 (9), 
but our results render support for the covalent mode of 
action of the 5-trifluoromethyl-2-pyridylsulfone class of 
PPARβ/δ antagonists [24]. Moreover, non-covalent and 
covalent docking of CC618 (10a) and GSK3787 (9) to the 





General information: All commercially available reagents 
and solvents were used in the form they were supplied 
without any further purification. The stated yields are based 
on isolated material. The melting points are uncorrected. 
Thin layer chromatography was performed on silica gel 60 
F254 aluminum-backed plates fabricated by Merck. Flash 
column chromatography was performed on silica gel 60 (40 
- 63 µm) fabricated by Merck. NMR spectra were recorded 
on a Bruker AVII-400 or a Bruker DPX-300 spectrometer at 
400 or 300 MHz, respectively, for 1H NMR and at 101 or 75 
MHz, respectively, for 13C NMR. Coupling constants (J) are 
reported in Hz and chemical shifts are reported in parts per 
million (δ) relative to the central residual solvent resonance 
in 1H NMR (CDCl3 = δ 7.27 and DMSO-d6 = δ 2.50) and 
the central carbon solvent resonance in 13C NMR (CDCl3 = 
δ 77.00 ppm and DMSO-d6 = δ 39.43). Mass spectra were 
recorded at 70 eV on a Waters Prospec Q spectrometer 
using EI as the method of ionization. High-resolution mass 
spectra were recorded on a Waters Prospec Q spectrometer 
using EI as the method of ionization. Determination of 
chemical purity of intermediates and final products was 
performed by HPLC on an Agilent Technologies 1200 
Series instrument with a diode array detector set at 254 nm 
and equipped with a C18 reverse phase column (Eclipse 
XDB-C18). The compounds 10a and 10b were >98% 
chemically pure, as judged by HPLC analyses. The TFA-
salts 15a and 15b were prepared by deprotection of the 
corresponding N-tert butyl carbamates [24] with TFA in 
MeCN and used without further purification. Compounds 13 
[30] and 14 [10] are known compounds. GSK3787 (9) [24] 
and GW501516 (1) [10] were prepared as previously 
described. Ammonium bicarbonate (ABC), 1,4-dithiothreitol 
(DTT), iodoacetic acid (IAA) all of analytical grade, formic 
acid for mass spectrometry (FA, ~98%), and sequencing 
grade L-1-Tosylamide-2-phenylethyl chloromethyl ketone 
(TPCK)-treated trypsin from bovine pancreas were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Acetonitrile hypergrade for LC-MS (MeCN) and dimethyl 
sulfoxide (DMSO, dried p.a.) were purchased from Merck, 
Darmstadt, Germany. MilliQ™ (mqH2O) water was 
produced in-house using a MilliQ™-system (Merck 
Millipore, Billerica, MA, USA). 
Ethyl 4-methyl-2-4-(trifluoromethyl)phenyl-1,3-thiazole-
5-carboxylate (13): [30] To a suspension of 4-
(trifluoromethyl)-thiobenzamide (3.0 g, 14.7 mmol.) in 
EtOH (150 mL) was added, at room temperature, ethyl 2-
chloroacetoacetate (2.4 g, 2.0 ml, 14.7 mmol). The solution 
was refluxed for 40 h, and the solvent removed under 
reduced pressure. The solid material was stirred with cold 
hexane (50 mL) for 60 min, filtered, and washed with 
hexane (2 × 25 mL). Drying gave compound 13 (3.5 g, 
75%) that was sufficiently pure for use in the next step. The 
spectroscopic data were in accord with those published. 1H 
NMR (300 MHz, CDCl3): δ 8.05 (d, J = 8.1 Hz, 2H), 7.70 
(d, J = 8.1 Hz, 2H), 7.35 (q, J = 7.0 Hz, 2H), 2.77 (s, 3H), 
1.40 (t, J = 7.0 Hz, 3H). 
4-Methyl-2-4-(trifluoromethyl)phenyl-1,3-thiazole-5-
carboxylic acid (14): [10] To a cooled solution of 13 (3.5 g, 
11.1 mmol) in EtOH (20 mL) was added an aqueous 
solution of NaOH (20 mL of 6 M, 120.0 mmol) and the 
mixture was heated at 75 - 85 °C for 2 h. After evaporation 
of the ethanol under reduced pressure, the aqueous solution 
was diluted with water (20 mL) and acidified to pH 1 with 
concentrated aqueous HCl. The precipitated solid material 
was filtered and washed with water (2 × 10 mL) and CH2Cl2 
(10 mL). After drying on a vacuum pump, acid 14 (2.9 g, 
92%) was obtained as a colorless powder that was 
sufficiently pure for use in the next step. The data was in 
accord with that published. 1H NMR (300 MHz, DMSO-d6): 
δ 13.20-13.45 (bs, 1H), 8.14 (d, J = 8.3 Hz, 2H), 7.84 (d, J = 
8.3 Hz, 2H), 2.66 (s, 3H). 
4-Methyl-2-(4-(trifluoromethyl)phenyl)-N-(2-(5-
(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)thiazole-5-
carboxamide (10a): To a stirred solution of 2-(5-
(trifluoromethyl)pyridin-2-ylsulfonyl)ethanamine TFA salt 
(15a, 115 mg, 0.4 mmol) [24] and 4-methyl-2-(4-
(trifluoromethyl)phenyl)thiazole-5-carboxylic acid (14) (150 
mg, 0.4 mmol) in CH2Cl2 (20 mL), triethylamine (360 μL, 
2.6 mmol) was added. To this mixture N,N'-
dicyclohexylcarbodiimide (124 mg, 0.6 mmol) and 1-
hydroxybenzotriazole (81 mg, 0.6 mmol) were then added. 
The reaction mixture was stirred overnight at ambient 
temperature. The mixture was washed with H2O (3 x 50 mL) 
and the remaining organic phase was dried (MgSO4) and 
concentrated. The residue was purified by column 
chromatography on silica gel with hexane/ethyl acetate (1:1) 
to obtain the title compound as a colorless solid (147 mg, 
72%). Mp 181 - 182°C. The purity (> 98%) was determined 
by HPLC analysis (Eclipse XDB-C18, MeOH/H2O, 7:3, 1.0 
mL/min): tr(major) = 7.61 min. 1H NMR (400 MHz, 
DMSO-d6): δ = 9.18 (s, 1H), 8.56 (dd, J = 8.2, 1.5 Hz, 1H), 
8.28-8.20 (m, 2H), 8.10 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.3 
Hz, 2H), 3.88 (t, J = 6.1 Hz, 2H), 3.68-3.60 (m, 2H), 2.57 (s, 
3H). 13C NMR (100 MHz, DMSO-d6): δ = 164.0, 160.5, 
160.0 (q, J = 1.4 Hz), 156.1, 147.3 (q, J = 3.5 Hz), 137.0 (q, 
J = 3.2 Hz), 135.8 (q, J = 1.2 Hz), 130.5 (q, J = 32.3 Hz), 
128.2 (q, J = 33.1 Hz), 126.9, 126.3 (q, J = 3.9 Hz), 126.2, 
124.0 (q, J = 272.4 Hz), 122.2 (q, J = 273.4 Hz), 121.3, 
50.3, 33.8, 17.0. HRMS calcd. for C20H15F6N3O3S2 [M]+: 
523.0459; found: 523.0446. 
4-Methyl-2-(4-(trifluoromethyl)phenyl)-N-(2-(pyridin-2-
ylsulfonyl)ethyl)thiazole-5-carboxamide (10b): A solution 
of tert-butyl (2-(pyridin-2-ylsulfonyl)ethyl)carbamate [24] 
(214 mg, 0.75 mmol) in MeCN (3 mL) was cooled on an 
ice/water bath for a period of 5 minutes, followed by the 
dropwise addition of trifluoroacetic acid (3 mL). The 
solution was stirred for 48h at ambient temperature, by 
which time the starting material had been consumed, as 
observed by TLC. The volatiles were removed at 60 °C 
under reduced pressure, using a water aspirator. Toluene 
was added to the crude material and the solvent was 
removed under the same conditions as above. The resulting 
slightly brown oil and 4-methyl-2-(4-
(trifluoromethyl)phenyl)thiazole-5-carboxylic acid (14) (216 
mg, 0.75 mmol) were dissolved in CH2Cl2 (10 mL) and 
triethylamine (0.7 mL, 5.03 mmol) was added. To this 
mixture N,N'-dicyclohexylcarbodiimide (239 mg, 1.16 
mmol) and 1-hydroxybenzotriazole (189 mg, 1.12 mmol) 
were then added. The reaction mixture was stirred at 
ambient temperature for 72h, diluted with CH2Cl2 (20 mL), 
and the organic phase washed with H2O (4 x 15 mL), dried 
(MgSO4) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica 
gel with heptane/ethyl acetate (1:1) to obtain the title 
compound as a colorless solid (121 mg, 35%). The purity (> 
98%) was determined by HPLC analysis (Eclipse XDB-
C18, MeOH/H2O, 6:4, 1.0 mL/min): tr(major) = 11.88 min. 
1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 4.6 Hz, 1H), 8.11 
(d, J = 7.8 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.98 (partial t, 
J = 7.8 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.56 (dd, J = 7.7, 
4.8 Hz, 1H), 7.05 (bt, J = 5.8 Hz, 1H), 3.99 (q, J = 5.7 Hz, 
2H), 3.71 (dd, J = 7.0, 4.3 Hz, 2H), 2.74 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 165.5, 161.5, 157.0, 156.5, 150.2, 
138.4, 135.8 (q, J = 1.3 Hz), 132.2 (q, J = 32.8 Hz), 127.7, 
126.8 (s, 2C), 126.7, 125.9 (q, J = 3.8 Hz, 2C), 123.7 (q, J = 
272.4 Hz), 122.0, 51.8, 33.8, 17.4. 1H NMR (400 MHz, 
DMSO-d6) δ 8.78 (d, J = 4.7 Hz, 1H), 8.36 (bt, J = 5.5 Hz, 
1H), 8.16 (partial t, J = 7.9 Hz, 1H), 8.13 (d, J = 7.7 Hz, 
2H), 8.08 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.1 Hz, 2H), 7.72 
(dd, J = 7.6, 4.8 Hz, 1H), 3.77 (t, J = 6.6 Hz, 2H), 3.61 (q, J 
= 6.3 Hz, 2H), 2.59 (s, 3H). 13C NMR (101 MHz, DMSO-
d6) δ 163.9, 160.6, 156.5, 155.6, 150.2, 139.0, 135.7 (q, J = 
1.3 Hz), 130.4 (prq, J = 32.0 Hz), 128.0, 126.9 (s, 2C), 
126.8, 126.2 (q, J = 3.8 Hz, 2C), 123.8 (prq, J = 272.4 Hz), 
121.7, 50.1, 33.6, 16.9. HRMS calcd. for C19H16F3N3O3S2 
[M]+: 455.0585; found: 455.0578. 
In vitro luciferase assays 
Antagonist measurements in luciferase-based transient 
reporter system: [25,41] Cos-1 cells (ATCC no. CRL-
1650) were maintained in DMEM (Invitrogen, Carlsbad, 
CA) containing gentamicin (10 μg/mL) and fetus bovine 
serum (10%), at 37 °C in a humidified atmosphere of 5% 
CO2. Cell confluence never exceeded 80% before sub-
culturing or transfection. The pSG5-Gal4-hPPAR-LBD (α, γ 
and β/δ subtypes) expression constructs were generous gifts 
from Dr. Hilde Nebb, University of Oslo, and the pGL3-
5XUAS-SV40 luciferase reporter construct was purchased 
from Promega Corporation, Madison, WI. Cos-1 cells were 
transiently transfected with 1.7 µg of the expression 
plasmids and 8.5 µg of the reporter construct per 1 x 107 
cells. Transient transfection was achieved using the Neon 
electroporation system (Invitrogen). Cells were seeded (2 x 
104/well) in 96-plates (white F96 microwell, Nalge Nunc 
Int., Rochester, NY) and allowed to attach (5 hours) before 
the test compounds were added. Transfected cells were 
treated for 19 hr with either CC618 (10a) or 10b in dilution 
series, as indicated on the x-axis in Figure 2a and in Figure 
S1, using vehicle supplemented with 4 nM of the PPARβ/δ 
agonist GW501516 (1). All values are given relative to the 
luciferase activity obtained by activating the reporter gene 
system with 4 nM GW501516 (1). For comparison, the 
antagonist activity of GSK3787 (9) is demonstrated in the 
same assay system. All values are relative to the luciferase 
activity obtained by activating the reporter gene system with 
207 μM of GW501516 (1), as indicated on the x-axis in 
Figure S2, The EC50-value of GW501516 (1) was found to 
be 0.5 nM. Luc protein expression was developed (One-Glo 
Luc assay system, Promega Biosciences, CA USA) and 
quantified on a luminometer (Envison, PerkinElmer, MA, 
US). The figures were generated using GraphPad Prism 
version 6.0, GraphPad Software, La Jolla, California, USA. 
Liquid Chromatography – Mass Spectrometry: 
Ligand treatment and in-solution digestion of N-His6-
PPARβ/δ: Human recombinant N-His6-PPARβ/δ (10 µg, 1 
mg/mL, Cayman Chemical), stored at -80 °C (CO2 (s)), was 
thawed on an ice/water bath, diluted to a concentration of 50 
µg/mL using 190 µL of freshly made 50 mM ABC buffer, 
fractionated to 10 stock solutions of 20 µL and subsequently 
refrozen at -30 °C. Prior to ligand treatment and in-solution 
digestion, 10 µL of the above described 50 µg/mL stock 
solution of human recombinant N-His6-PPARβ/δ was 
thawed on ice in a Protein LoBind Eppendorf tube 
(Eppendorf AG, Hamburg, Germany) and subsequently 
diluted with 10 µL of a freshly made solution of 375 µM of 
DTT in 50 mM ABC buffer. The solution was left on ice for 
5 min and then added 10 µL of a 30 µM solution of 
compound 9 or 10a in 50 mM ABC buffer (w/0.039% of 
MeCN), resulting in a final concentration of 125 µM of 
DTT [42] and 10 µM of ligand. The solution was incubated 
at ambient temperature for 15 min, diluted with 55 µL of 50 
mM ABC buffer and added 5 µL of a solution containing 50 
mM DTT in 50 mM ABC buffer. After incubation for 15 
minutes at 95 °C and subsequent cooling to ambient 
temperature, 5 µL of a freshly prepared solution of 250 mM 
iodoacetic acid (IAA) in 50 mM ABC buffer was added and 
the solution was incubated in the dark at ambient 
temperature for 20 minutes. Following alkylation, 5 µL of  a 
freshly prepared solution of containing 2.5 µg/mL bovine 
trypsin in 50 mM ABC buffer (trypsin:protein ratio, 1:40 
(w/w)) was added and the sample was incubated at 37 °C 
overnight using a Thermomixer Comfort (Thermo 
Scientific) at 800 rpm. The final protein concentration was 5 
µg/mL in all experiments. 
LC-MS/MS analysis: Samples of 20 µL of the proteolytic 
peptide mixtures were injected into the Chromeleon Xpress-
controlled Dionex HPLC system (Thermo Scientific, 
Bremen, Germany) and trapped on a C18, 5 mm x 300 μm 
i.d. Acclaim PepMap 100 (5 μm) enrichment column 
(Thermo Scientific). The loading mobile phase consisting of 
3% MeCN, 0.1% FA and 97% mqH2O, was delivered at 10 
μL/min for 4 minutes. The analytes were transferred to a 
150 × 0.075 mm i.d. Acclaim PepMap 100 (pore size 100 Å, 
particle diameter 3 μm; Thermo Scientific) at 300 nL/min. 
The mobile phases consisted of A: 5% MeCN, 3% DMSO, 
0.1% FA and 92% mqH2O, and B: 95% MeCN, 3% DMSO, 
0.1% FA and 2% mqH2O. A linear gradient was run from 
0% to 50% B in 60 minutes. Subsequently, the elution 
strength was increased to 100% B, before the column was 
regenerated for at least 10 column volumes. Total analysis 
time per run was 87 minutes. The LC setup was connected 
to an Xcalibur 2.0.7-controlled LTQ Discovery Orbitrap MS 
equipped with a Nano-ESI ion source (Thermo Fischer). The 
nanospray ionization source was operated in the positive 
ionization mode (360 μm o.d. × 20 μm i.d. distal coated 
fused silica emitter, 10 μm i.d. tip (New Objective, Woburn, 
MA, USA)). The spray voltage was set at 2.2 kV. The 
heated capillary was kept at 275 °C. The capillary voltage 
was set at 45 V and the tube lens offset at 120 V. The mass 
spectrometer was operated in data-dependent positive ion 
mode. Survey MS scans were performed in the orbitrap 
analyzer at a resolution of 30000, over a mass range 
between m/z 250 - 2000 Da, with charge state disabled. The 
up to 6 most intense ions per scan were fragmented by 
collision induced dissociation (CID) at 35% relative 
collision energy, activation time of 30 ms, minimum signal 
required of 500 and analyzed in the linear ion trap. The wide 
band activation option was enabled and dynamic exclusion 
of a time window of 15 seconds was used to minimize the 
extent of repeat sequencing of the peptides. 
Data interpretation: The MS raw files were processed with 
Proteome Discoverer 1.3 (Thermo Scientific), using the 
Sequest algorithm, searching against the FASTA file 
ipi.HUMANpr. May 22, 2014. Enzyme specificity was set 
to trypsin. The initial parent and fragment ion maximum 
mass deviations were set to 10 ppm and 0.6 Da, 
respectively. The search included cysteine 
carboxymethylation and 5-CF3-2-pyridyl modification of 
cysteine, histidine, arginine or lysine as variable 
modifications. Peptides had to be fully tryptic, and up to two 
missed cleavages were allowed. A decoy database search 
was performed by searching against a database containing 
the reversed protein sequences with a strict target false 
discovery rate (FDR) of 0.01 and a relaxed FDR of 0.05.   
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